This report reviews Europe’s 15-year experience with biosimilars, analyzing their impact on access, pricing, and healthcare system sustainability. It shows that biosimilars have delivered significant cost savings and expanded patient access, particularly in hospital-administered therapies. Adoption rates vary widely across countries due to differences in procurement models, incentives, and clinician confidence. The report highlights best practices, including physician engagement, gainsharing programs, and clear switching policies. Europe’s experience offers lessons for other regions seeking to balance affordability with sustainable competition and continued pharmaceutical innovation.

Join for free to read